Category: Cardiac Rhythm ManagementSyndicate content

Boston Scientific launches trial for Acuity X4, Reliance 4-Front leads

April 23, 2014 by Brad Perriello

Boston Scientific launches a clinical trial for its Acuity X4 pacemaker and Reliance 4-Front defibrillator leads, ahead of its bid for U.S. FDA approval of the devices.

keys: boston scientific, bsx, acuity x4, reliance 4-front

Medtronic begins U.S. IDE trial for Evera SureScan MRI-safe ICD

April 23, 2014 by Brad Perriello

Medtronic announces the 1st implantation in a U.S. investigational device exemption trial for its Evera SureScan MRI-safe implantable cardioverter-defibrillator.

Medtronic begins U.S. IDE trial for Evera SureScan MRI-safe ICD

Medtronic (NYSE:MDT) said the 1st patient was implanted with its MRI-safe Evera SureScan ICD as part of an investigational device exemption trial in the U.S.

St. Jude Medical beats The Street, loses points anyway

April 16, 2014 by Arezu Sarvestani

St. Jude Medical meets Wall Street's expectations for its 1st quarter of 2014 with moderate sales growth across its product lines, but shares take a downward turn in morning trading.

St. Jude Medical meets The Street, loses points anyway

Minnesota medtech titan St. Jude Medical (NYSE:STJ) lost a few points on Wall Street today after posting 1st quarter earnings a penny above analysts' consensus estimate.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Boston Scientific lands FDA approval for next-gen heart devices

April 16, 2014 by Arezu Sarvestani

Boston Scientific gets the FDA's OK for a new generation of defibrillators and heart failure devices, including some of the world's smallest and thinnest ICDs.

Boston Scientific lands FDA approval for next-gen heart devices

Boston Scientific (NYSE:BSX) announced this week that it won FDA approval for its newest suite of cardiac devices, including next-generation defibrillators and heart failure devices.

FDA expands indication for Medtronic pacemakers, defibs

April 11, 2014 by Brad Perriello

The FDA expands the indication for Medtronic's cardiac rhythm management devices to include bi-ventricular pacing in certain patients.

FDA expands indications for Medtronic pacemakers, defibs

Medtronic (NYSE:MDT) said the FDA expanded the indication for some of its cardiac rhythm management devices to include bi-ventricular pacing in certain heart failure patients.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

InfoBionic lands $17M for remote patient monitoring

April 10, 2014 by Arezu Sarvestani

InfoBionic raises $17 million in a Series B financing round supporting its cloud-, smartphone- and web-based remote patient monitoring systems.

Infobionic lands $17M for remote patient monitoring

Digital health startup InfoBionic secured $17 million in Series B financing in support of its remote patient monitoring platform.

InfoBionic plans to use the funds to commercialize its MoMe monitoring platform, which utilizes cloud, smartphone and web services that connect with sensors worn by patients. The company's current focus is on cardiac arrhythmias.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Medtronic wins CE Mark for Evera MRI SureScan ICD

April 9, 2014 by Brad Perriello

Medtronic says it won CE Mark approval in the European Union for its Evera MRI SureScan implantable cardiac defibrillator, claiming it as the world's 1st ICD approved for full-body magnetic resonance imaging scans.

Medtronic wins CE Mark for Evera MRI SureScan ICD

Medtronic (NYSE:MDT) said it won CE Mark approval in the European Union for the world's 1st market-cleared implantable cardiac defibrillator that's safe for full-body magnetic resonance imaging scans, its Evera MRI SureScan ICD.

The Evera device is slated for an immediate launch in Europe, according to a press release.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp